Allarity Therapeutics (ALLR) Regains Nasdaq Compliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024 7:00 AM EDTBoston (April 29, 2024) Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLCs Office of General Counsel (Nasdaq). This notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaqs Listing Rule 5550(a)(2) (the Bid Price Rule). Nasdaq noted that since April 9, 2024, Allaritys stock has maintained a closing bid price above $1.00 per share for more than ten consecutive trading days, thereby... More
